Abramson Cancer Center Support Grant
Abramson Cancer Center Support Grant
批准号:
10425591
负责人:
ROBERT H VONDERHEIDE
金额:
$19.94万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-01 至 2022-08-31
关键词:
Acquired Immunodeficiency SyndromeAddressAdherenceAfrica South of the SaharaAfricanAftercareBotswanaCancer Center Support GrantCancer SurvivorCaringCessation of lifeCharacteristicsClinicClinicalConsolidated Framework for Implementation ResearchCountryDataDeveloping CountriesDiagnosisEarly DiagnosisEarly treatmentEnsureFutureGeographyGoalsGrantGynecologic OncologyHIVHIV InfectionsHospitalsIncidenceIncomeInterventionInterviewMalignant NeoplasmsMalignant neoplasm of cervix uteriMethodsMorbidity - disease rateOutcomePatient-Focused OutcomesPatientsPatternPersonsPrevalencePrivate HospitalsQuality of lifeRadiation therapyRecommendationResearchResourcesScientific Advances and AccomplishmentsShapesStructureSurveysTestingWomanWorkadvanced diseaseanticancer researchcare deliverycare outcomescohortcontextual factorscurative treatmentsdemographicsexperiencefallsimprovedinfection rateinterestlow and middle-income countriesmortalitymultidisciplinaryoutreach clinicspsychosocialresponsescreeningsurvivorshiptransportation accesstumoruptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-
21-058. The number of cancer survivors living in low- and middle-income countries (LMICs) is expected to grow
rapidly over the next decade driven in part by global advances in early detection and treatment, yet very little is
known about the long-term needs of cancer survivors or delivery of survivorship care in LMICs. This supplement
application will help to fill this critical research gap by quantitatively and qualitatively evaluating care outcomes
and contextual determinants of survivorship care among women diagnosed with cervical cancer in Botswana.
Cervical cancer is one of the leading cancers among women globally with 600,000 new cases and 340,000
deaths annually per 2020 estimates. Cervical cancer is an acquired immunodeficiency syndrome (AIDS)-defining
malignancy, and countries with high rates of human immunodeficiency virus (HIV) have higher incidence of
cervical cancer. Due to high HIV-infection rates and suboptimal screening uptake, most of the burden of cervical
cancer incidence, morbidity, and mortality falls on LMICs particularly in sub-Saharan Africa, with many women
presenting with advanced disease. Botswana, a sub-Saharan African country, has high rates of cervical cancer
(incidence rate of 34.4 per 100,000) and HIV (18.5% prevalence), and a high rate of mortality due to cervical
cancer (20.1 per 100,000) among women. To date, the majority of cancer research in Botswana and other LMICs
has focused on early detection or treatment, with limited research evaluating the long-term physical or
psychosocial outcomes in survivorship or how survivorship care may impact these outcomes. Furthermore, even
less is known regarding which approaches may be most impactful and sustainable to deliver survivorship care
in LMICs. As such, there is a critical need to understand the current state of survivorship in LMICs and to identify
effective strategies to ensure that all women receive optimal survivorship care. The objectives of this project are
to: 1) quantitatively describe a) patterns in post-treatment survivorship care and b) long-term physical and
psychosocial sequelae of cervical cancer using an existing cohort of patients at Princess Marina Hospital in
Gaborone, Botswana; and 2) qualitatively assess contextual determinants (e.g., quality of life, access to
resources, care delivery strategies) shaping patient experiences and adherence to survivorship care. In
combination, these data will be used to develop and/or adapt survivorship care interventions to target the specific
contextual determinants in Botswana and other LMICs. The results of this project will advance scientific
understanding of survivorship care and sequelae in LMICs and how these experiences may or may not differ
from the experiences and needs of cancer survivors in high-income countries. This project will also generate
fundamental evidence needed to improve survival and quality of life of cancer survivors globally. The long-term
goal of this project is to decrease cervical cancer mortality in Botswana and other LMICs by developing and
implementing survivorship care interventions that can be sustained in lower resource settings.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Abramson Cancer Center Support Grant.
-
批准号:10367691
-
项目类别:
-
资助金额:$16.25万
-
财政年份:2021
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Abramson Cancer Center Support Grant
-
批准号:10408409
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2021
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Abramson Cancer Center Support Grant
-
批准号:10469216
-
项目类别:
-
资助金额:$36.76万
-
财政年份:2021
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Abramson Cancer Center Support Grant
-
批准号:10372715
-
项目类别:
-
资助金额:$11.5万
-
财政年份:2021
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients
-
批准号:10249752
-
项目类别:
-
资助金额:$7.34万
-
财政年份:2019
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
non-AIDS defining cancers (NADCs) among aging HIV+ individuals
-
批准号:10249743
-
项目类别:
-
资助金额:$7.93万
-
财政年份:2019
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
-
批准号:10005190
-
项目类别:
-
资助金额:$64.61万
-
财政年份:2017
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Core A: Administration
-
批准号:10005186
-
项目类别:
-
资助金额:$6.77万
-
财政年份:2017
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Core A: Administration
-
批准号:10360420
-
项目类别:
-
资助金额:$6.77万
-
财政年份:2017
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Program Integration
-
批准号:10360426
-
项目类别:
-
资助金额:$1.64万
-
财政年份:2017
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients
-
批准号:10360423
-
项目类别:
-
资助金额:$63.93万
-
财政年份:2017
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Program Integration
-
批准号:10005193
-
项目类别:
-
资助金额:$1.64万
-
财政年份:2017
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Combined CD40 activation and CTLA4 blockade in melanoma
-
批准号:8084679
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2011
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Combined CD40 activation and CTLA4 blockade in melanoma
-
批准号:8460948
-
项目类别:
-
资助金额:$31.21万
-
财政年份:2011
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Combined CD40 activation and CTLA4 blockade in melanoma
-
批准号:8848307
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2011
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Combined CD40 activation and CTLA4 blockade in melanoma
-
批准号:8657906
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2011
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Combined CD40 activation and CTLA4 blockade in melanoma
-
批准号:8300098
-
项目类别:
-
资助金额:$33.2万
-
财政年份:2011
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Immunoregulation and immunotherapy of breast cancer
-
批准号:8193071
-
项目类别:
-
资助金额:$31.04万
-
财政年份:2005
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Immunoregulation and immunotherapy of breast cancer
-
批准号:7729898
-
项目类别:
-
资助金额:$32.75万
-
财政年份:2005
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
Immunoregulation and immunotherapy of breast cancer
-
批准号:6969221
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2005
-
负责人:ROBERT H VONDERHEIDE
-
依托单位:
海外基金